Clomipramine Hydrochloride in Childhood and Adolescent Obsessive-Compulsive Disorder—a Multicenter Trial

JOSEPH DEVEAUGH-GEISS, GEORGES MOROZ, JOSEPH BIEDERMAN, DENNIS CANTWELL, REJEAN FONTAINE, JOHN H. GREIST, ROBERT REICHLER, RICHARD KATZ, PHYLLIS LANDAU

Research output: Contribution to journalArticlepeer-review

291 Scopus citations

Abstract

Children and adolescents with obsessive compulsive disorder were studied in an 8-week, multicenter, double-blind, parallel groups trial of clomipramine hydrochloride (CMI) versus placebo. Efficacy assessments included the child version of the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global rating scale. At the end of 8 weeks, CMI-treated patients showed a mean reduction in Yale-Brown Obsessive Compulsive Scale score of 37% compared to 8% in the placebo group. Side effects were typical of tricyclic antidepressants. In a 1-year open label treatment, CMI continued to be effective and well tolerated. J. Am. Acad. Child Adolesc. Psychiatry, 1992, 31, 1:45–49.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume31
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Keywords

  • Y-BOCS
  • clomipramine
  • compulsion
  • obsession
  • obsessive-compulsive disorder

Fingerprint

Dive into the research topics of 'Clomipramine Hydrochloride in Childhood and Adolescent Obsessive-Compulsive Disorder—a Multicenter Trial'. Together they form a unique fingerprint.

Cite this